With a $1.8 billion purchase with CinCor, AstraZeneca grows its heart and kidney businesses.

9 January (Reuters) AstraZeneca (AZN.L) declared on Monday that it has reached an agreement to acquire American drug-development company CinCor Pharma Inc (CINC.O) for up to $1.8 billion in order to expand its supply of heart and kidney medications.

The experimental medication baxdrostat, which is being developed by CinCor to treat illnesses like high blood pressure and chronic renal disease, is at the heart of the agreement.

Read More

Enjoy this blog? Please spread the word :)

Follow by Email
With the latest update, you can now specify whether employees are off on public holidays directly in their work schedule. Kerry brown | contemporary china expert, author, and speaker | cwg speakers. درمان پوسیدگی دندان از بین بردن عصب.